Metrics as of 10/16/2026, 06:30 PM (Berlin time), refresh in progress.
Allogene Therapeutics Stock
Allogene Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Zachary Roberts
- Employees
- 151
- Market cap
- $453 M
- IPO
- 11/10/2018
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor…
Allogene Therapeutics stock: price history
1D
-2.2%
1W
-10.3%
1M
-22.5%
6M
-45.2%
YTD
-4.4%
1Y
+3.1%
2Y
-54.0%
5Y
-92.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~10% stronger price swings than usual
Allogene Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T-cell therapies for treating various cancers, including acute lymphoblastic leukemia and lymphomas. The company's product pipeline comprises multiple drug candidates in different clinical trial phases, including UCART19 and ALLO-501. The current business model generates revenues entirely from licensing agreements as part of strategic alliances. The company's focus lies on the research, development, and clinical evaluation of its specialized therapeutic candidates.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Pfizer Inc.Description
Cellectis S.A.DescriptionAsk the agents about Allogene Therapeutics
Analyst assessment of Allogene Therapeutics
PRICE TARGET LOW
US$3.85
CONSENSUS
US$26.53
MEDIAN
US$32.00
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
19
BUY
10
HOLD
1
SELL
0
STRONG SELL
30
TOTAL · Buy
As of: 17/08/2026
Allogene Therapeutics stock metrics
P/E
-1.96
P/B
0.99
EV/EBITDA
-3.18
RETURN ON EQUITY
-9.8%
NET MARGIN
-919.8%
DEBT/EQUITY
0.16
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.6%
FLOAT SHARES
257,830,951
AVG. DAILY VOLUME (30D)
5,887,273
Insider transactions (SEC)
Douglas Earl Martin
Kazam Joshua A
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.2%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Allogene Therapeutics stock
What does Allogene Therapeutics do?
Allogene Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Zachary Roberts, the company employs around 151 people.
The IPO was on 11/10/2018; the stock trades on NASDAQ under the ticker ALLO.
What do analysts say about Allogene Therapeutics stock?
30 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$26.53, ranging from US$3.85 to US$55.00, with a median of US$32.00.
This is an external assessment, not a statement by Market Jury.
When does Allogene Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Allogene Therapeutics pay a dividend?
No, Allogene Therapeutics currently does not pay a dividend.
Which stocks are comparable to Allogene Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Allogene Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Allogene Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.